Posted by Michael Wonder on 28 Feb 2026
Ontario becomes the first province to publicly reimburse the first targeted oral therapy for adults with grade 2 IDH-mutant glioma
27 February 2026 - Servier Canada announces Ontario coverage of Voranigo under the FAST program.
Servier Canada is pleased to announce that Voranigo (vorasidenib tablets) is now publicly reimbursed in Ontario under the province's Funding Accelerated for Specific Treatments (FAST) program.
